| CPC A61K 47/44 (2013.01) [A61K 8/31 (2013.01); A61K 8/342 (2013.01); A61K 8/361 (2013.01); A61K 9/0014 (2013.01); A61K 9/0048 (2013.01); A61K 9/12 (2013.01); A61K 9/122 (2013.01); A61K 9/124 (2013.01); A61K 31/137 (2013.01); A61K 31/192 (2013.01); A61K 31/4164 (2013.01); A61K 31/57 (2013.01); A61K 31/573 (2013.01); A61K 31/593 (2013.01); A61K 31/65 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/24 (2013.01); A61Q 17/04 (2013.01); A61Q 19/00 (2013.01); A61Q 19/10 (2013.01); A61K 2800/31 (2013.01); A61K 2800/33 (2013.01)] | 23 Claims |
|
1. A method of treating rosacea, comprising administering a foamable composition comprising a carrier and a liquefied or compressed gas propellant, the carrier comprising:
a) a tetracycline antibiotic;
b) at least one hydrophobic oil; and
c) an agent comprising (i) at least one fatty alcohol and at least one wax; (ii) at least one fatty acid and at least one wax; (iii) at least one fatty alcohol, at least one fatty acid, and at least one wax; (iv) a wax comprising a hydrogenated oil; or
(v) a combination of two or more waxes;
wherein the carrier does not comprise a surfactant;
wherein the composition has an Aw value of about 0.9 or less; and
wherein upon release from an aerosol container the composition forms a foam.
|